Type 1 Diabetes Pipeline Analysis Report 2026

Type 1 Diabetes continues to present a substantial global health burden, characterized by autoimmune-mediated destruction of pancreatic beta cells and lifelong insulin dependence. An estimated 9.5 million people were living with type 1 diabetes worldwide in 2025, reflecting sustained epidemiological growth and improved survival trends. As disease awareness increases and early screening improves, innovation is accelerating across immunotherapies, cell-based approaches, and advanced insulin formulations. According to the analyst, the type 1 diabetes pipeline analysis highlights a strong mid-stage clinical landscape, signaling steady therapeutic evolution and long-term market potential.

Report Coverage

The Type 1 Diabetes Pipeline Analysis Report gives comprehensive insights into type 1 diabetes therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for type 1 diabetes. The type 1 diabetes report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The type 1 diabetes pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with type 1 diabetes treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to type 1 diabetes.

Type 1 Diabetes Pipeline Outlook

The type 1 diabetes pipeline outlook reflects a shift beyond lifelong insulin replacement toward disease-modifying and more accessible therapeutic options.

Type 1 diabetes treatment relies on intensive insulin therapy, including rapid-acting and long-acting insulin analogs, supported by continuous glucose monitoring and insulin pump technologies to maintain glycemic control. For instance, in February 2025, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj), the first rapid-acting insulin biosimilar to improve glycemic control in adults and pediatric patients with diabetes mellitus. This approval represents a significant step in expanding more affordable insulin options while next-generation immunotherapies and beta-cell-preserving strategies continue advancing in the pipeline.

Type 1 Diabetes Epidemiology

Type 1 diabetes remains a significant and growing global health burden, with an estimated 9.5 million people living with the disease worldwide in 2025. The epidemiology reflects improved survival rates, population growth, and increasing recognition across regions. A substantial proportion of affected individuals are aged 20-59 years, while children and adolescents continue to represent a meaningful share of cases. Notably, over one-fifth of people with type 1 diabetes reside in low- and middle-income countries, highlighting disparities in diagnosis and care access that continue to shape global disease outcomes.

Type 1 Diabetes - Pipeline Therapeutic Assessment

This section of the report covers the analysis of type 1 diabetes drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The type 1 diabetes pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptide

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Type 1 Diabetes Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total type 1 diabetes clinical trials. The report covers Phase I (28%), Phase II (43%), Phase III (14%), Phase IV (9%), and Early Phase I (6%) drugs. These findings highlight that mid-stage development dominates the type 1 diabetes pipeline, reflecting active clinical exploration and the potential for future therapeutic advancements.

Type 1 Diabetes Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the type 1 diabetes pipeline analysis include monoclonal antibodies, small molecules, and peptides. The type 1 diabetes report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for type 1 diabetes. In June 2023, the U.S. Food and Drug Administration approved Lantidra (donislecel), the first allogeneic pancreatic islet cell therapy for adults with type 1 diabetes and recurrent severe hypoglycemia. This therapy uses donor islet cells to produce insulin, offering a novel therapeutic option beyond traditional management for patients struggling with severe low blood sugar.

Type 1 Diabetes Clinical Trials - Key Players

The report for the type 1 diabetes pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed type 1 diabetes therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in type 1 diabetes clinical trials:

• Creative Medical Technology Holdings Inc
• PolTREG S.A.
• Vertex Pharmaceuticals Incorporated
• Novo Nordisk A/S
• SAb Biotherapeutics, Inc.
• Sanofi
• vTv Therapeutics
• GentiBio, Inc
• Eli Lilly and Company
• COUR Pharmaceutical Development Company, Inc.

Type 1 Diabetes - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for type 1 diabetes. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of type 1 diabetes drug candidates.

Drug: SAR442970

SAR442970 is an investigational anti-CD40L monoclonal antibody developed by Sanofi that targets both tumor necrosis factor-α (TNF-α) and OX40L to modulate adaptive immune responses. By simultaneously inhibiting these inflammatory pathways, it aims to reduce immune-mediated tissue damage and preserve organ function. Currently in Phase 2 trials across autoimmune indications, including type 1 diabetes and Crohn’s disease, Sanofi’s broader immunology portfolio leverages SAR442970’s unique dual-target approach to expand beyond single-pathway biologics in chronic inflammatory diseases.

Drug: RGB-5088

RGB-5088 is a regenerative islet cell therapy developed by Hangzhou Reprogenix Bioscience, Inc. that uses chemically induced pluripotent stem cell (CiPSC)-derived pancreatic islet cells to restore endocrine function in type 1 diabetes. In early Phase 1 trials, these transplanted islet cells aim to replace dysfunctional insulin-producing cells and normalize glucose regulation. Reprogenix leverages its stem cell and reprogramming expertise to advance RGB-5088, positioning it as a pioneering cellular approach that could reduce or eliminate dependence on exogenous insulin if successful.

Key Questions Answered in the Type 1 Diabetes Pipeline Insight Report

• Which companies/institutions are leading the type 1 diabetes drug development?
• Which company is leading the type 1 diabetes pipeline development activities?
• What is the current type 1 diabetes commercial assessment?
• What are the opportunities and challenges present in the type 1 diabetes pipeline landscape?
• What is the efficacy and safety profile of type 1 diabetes pipeline drugs?
• Which company is conducting major trials for type 1 diabetes drugs?
• Which companies/institutions are involved in type 1 diabetes collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in type 1 diabetes?

Reasons To Buy This Report

The Type 1 Diabetes Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for type 1 diabetes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into type 1 diabetes collaborations, regulatory environments, and potential growth opportunities.